financetom
Business
financetom
/
Business
/
eBay Q3 revenue up 9% to $2.8 bln, beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
eBay Q3 revenue up 9% to $2.8 bln, beats estimates
Oct 29, 2025 1:47 PM

Overview

* eBay ( EBAY ) Q3 revenue rises 9% to $2.8 bln, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company returned $757 mln to shareholders via repurchases and dividends

Outlook

* eBay ( EBAY ) sees Q4 revenue between $2.83 bln and $2.89 bln

* eBay ( EBAY ) expects full-year revenue between $10.97 bln and $11.03 bln

* eBay ( EBAY ) anticipates Q4 GAAP EPS of $0.96 to $1.01

* eBay ( EBAY ) projects full-year non-GAAP EPS of $5.42 to $5.47

Result Drivers

* STRATEGIC PARTNERSHIPS - Collaborations with brands like Marks & Spencer and expansion of the Authenticity Guarantee program boosted engagement and sales

* ACQUISITIONS - Acquisition of Tise strengthened eBay's ( EBAY ) C2C expertise and connection with Gen Z and Millennial shoppers

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.8 bln $2.73

Revenue bln (27

Analysts

)

Q3 Beat $1.36 $1.33

Adjusted (26

EPS Analysts

)

Q3 Beat $636 mln $616.86

Adjusted mln (19

Net Analysts

Income )

Q3 GMV $20.10

bln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 11 "strong buy" or "buy", 21 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the online services peer group is "buy."

* Wall Street's median 12-month price target for eBay Inc ( EBAY ) is $95.00, about 4.8% below its October 28 closing price of $99.58

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Endeavour Silver Swings to Adjusted Q1 Net Loss
Endeavour Silver Swings to Adjusted Q1 Net Loss
May 9, 2024
07:56 AM EDT, 05/09/2024 (MT Newswires) -- Endeavour Silver ( EXK ) on Thursday said it swung to an adjusted net loss in the first quarter. The miner reported a net loss of US$200,000, or US$0.00 per share, from adjusted net earnings of US$4.5 million, or US$0.02 per share. Revenue increased 15% to US$63.7 million while EBITDA slumped 30% to...
SharkNinja's Q1 Adjusted Net Income, Net Sales Rise; Fiscal 2024 Outlook Raised
SharkNinja's Q1 Adjusted Net Income, Net Sales Rise; Fiscal 2024 Outlook Raised
May 9, 2024
07:58 AM EDT, 05/09/2024 (MT Newswires) -- SharkNinja ( SN ) reported Q1 adjusted net income Thursday of $1.06 per share, up from $0.86 a year earlier. Analysts polled by Capital IQ expected $0.97. Net sales for the quarter ended March 31 were $1.07 billion, up from $855.3 million a year earlier. Analysts surveyed by Capital IQ expected $949.9 million....
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
May 9, 2024
07:56 AM EDT, 05/09/2024 (MT Newswires) -- HLS Therapeutics ( HLTRF ) reported a wider first quarter net loss than in the year earlier period as revenue fell. The company has also terminated its agreement with Pfizer. The pharmaceutical company reported net loss was US$6.1 million, or US$0.19 per share, compared with a net loss of US$5.8 million, or US$0.18...
BRIEF-Royalty Pharma To Acquire Royalty Interest  In Sanofi'S Frexalimab
BRIEF-Royalty Pharma To Acquire Royalty Interest In Sanofi'S Frexalimab
May 9, 2024
May 9 (Reuters) - Royalty Pharma PLC ( RPRX ): * ROYALTY PHARMA TO ACQUIRE ROYALTY INTEREST IN SANOFI'S FREXALIMAB * ROYALTY PHARMA ( RPRX ) : PROPOSED DEAL FOR APPROXIMATELY $525 MILLION IN CASH * ROYALTY PHARMA ( RPRX ) : EXPANDS CO'S DEVELOPMENT-STAGE PORTFOLIO TO 15 THERAPIES WITH COMBINED POTENTIAL TO GENERATE GREATER THAN $1 BILLION IN ANNUAL...
Copyright 2023-2026 - www.financetom.com All Rights Reserved